11/11
12:28 pm
mnpr
Monopar Therapeutics Inc. (NASDAQ: MNPR) had its price target raised by analysts at HC Wainwright from $6.00 to $22.00. They now have a "buy" rating on the stock.
Low
Report
Monopar Therapeutics Inc. (NASDAQ: MNPR) had its price target raised by analysts at HC Wainwright from $6.00 to $22.00. They now have a "buy" rating on the stock.
11/8
08:00 am
mnpr
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
Low
Report
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
10/30
01:42 pm
mnpr
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock
Low
Report
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock
10/28
09:19 pm
mnpr
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock [Yahoo! Finance]
Medium
Report
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock [Yahoo! Finance]
10/28
09:15 pm
mnpr
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
Medium
Report
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
10/28
04:00 pm
mnpr
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock
Low
Report
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock
10/28
01:30 pm
mnpr
Up 600% Then Down 50% In 2 Days: What Is Going On With MNPR Stock? [Forbes]
Medium
Report
Up 600% Then Down 50% In 2 Days: What Is Going On With MNPR Stock? [Forbes]
10/26
09:50 am
mnpr
Individual investors are Monopar Therapeutics Inc.'s (NASDAQ:MNPR) biggest owners and were rewarded after market cap rose by US$40m last week [Yahoo! Finance]
High
Report
Individual investors are Monopar Therapeutics Inc.'s (NASDAQ:MNPR) biggest owners and were rewarded after market cap rose by US$40m last week [Yahoo! Finance]
10/24
07:00 am
mnpr
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
High
Report
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
10/22
08:00 am
mnpr
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
Low
Report
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
10/15
08:00 am
mnpr
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers
Medium
Report
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers
10/11
08:07 am
mnpr
Monopar Therapeutics Inc. (NASDAQ: MNPR) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $50.00 price target on the stock.
Medium
Report
Monopar Therapeutics Inc. (NASDAQ: MNPR) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $50.00 price target on the stock.
10/7
08:00 am
mnpr
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers
Medium
Report
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers
9/12
08:00 am
mnpr
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
High
Report
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
9/4
08:00 am
mnpr
Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Medium
Report
Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
8/27
04:11 pm
mnpr
Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule [Yahoo! Finance]
Medium
Report
Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule [Yahoo! Finance]
8/27
04:05 pm
mnpr
Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule
Medium
Report
Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule